Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

We have an emerging new entrant in the increasingly crowded weight loss drug space.

The origins: Opened in 1958 by a Holocaust survivor as an aerospace liquidation business and surplus store, the Sun Valley ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). These ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what ...

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 mg option.

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

Diabetes and weight loss drug semaglutide has been trialled in people with Alzheimer's. We explain what it means for dementia ...

FTC finalizes order shutting down deceptive marketing by telemedicine firm NextMed • Company accused of hiding costs, faking ...